Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137258

Published: 2020

Journal Articles

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Alyssa Bouska, PhD, Weiwei Zhang, PhD, Qiang Gong, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Lu Chen, PhD, Rebecca Ottesen, Joyce Niland, PhD, Victoria Bedell, Maria Valle-Catuna, Joyce Murata-Collins, PhD, Dennis D. Weisenburger, MD, Javeed Iqbal, PhD, Elaine S. Jaffe, MD, Wing C. Chan, MD

Blood (2019) 134 (Supplement_1): 1486.

https://doi.org/10.1182/blood-2019-125095

Published: 2019

Journal Articles

New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2018) 132 (Supplement 1): 346.

https://doi.org/10.1182/blood-2018-99-117636

Published: 2018

Journal Articles

Mutations in the Phosphoinositide 3-Kinase Pathway (PI3K) Are Associated with Poor Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2017) 130 (Supplement 1): 2740.

https://doi.org/10.1182/blood.V130.Suppl_1.2740.2740

Published: 2017

Journal Articles

Mutation Spectrum of Transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma and Comparison with De Novo Diffuse Large B-Cell Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Qiang Gong, PhD, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Rebecca Ottesen, Joyce Niland, PhD, Dennis D. Weisenburger, MD, Elaine S. Jaffe, MD, Wing C Chan, MD

Blood (2017) 130 (Supplement 1): 1463.

https://doi.org/10.1182/blood.V130.Suppl_1.1463.1463

Published: 2017

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Anita Kumar, MD, Ann Vanderplas, Ann S. LaCasce, MD, MSc, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn Nademanee, M.D., Joyce Niland, PhD, Leo I. Gordon, MD, FACP, Michael Millenson, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH

Blood (2010) 116 (21): 1756.

https://doi.org/10.1182/blood.V116.21.1756.1756

Published: 2010

Journal Articles

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Karim E Abou-Nassar, MD, Ann Vanderplas, Jonathan W. Friedberg, MD, Gregory Abel, MD, MPH, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Allison Crosby, MS, Leo I Gordon, MD, FACP, Andrew D Zelenetz, MD, Ann LaCasce, MD, MSc

Blood (2010) 116 (21): 81.

https://doi.org/10.1182/blood.V116.21.81.81

Published: 2010

Journal Articles

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Gregory A. Abel, MD, MPH, Ann Vanderplas, MS, Jonathan W. Friedberg, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S Czuczman, MD, Michael Millenson, MD, Allison L. Crosby, Leo I. Gordon, MD, Douglas W. Blayney, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2009) 114 (22): 1387.

https://doi.org/10.1182/blood.V114.22.1387.1387

Published: 2009

Journal Articles

Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project.

Maria Alma Rodriguez, MD, Myron S. Czuczman, MD, Jonathan W. Friedberg, MD, Michelle E. Kho, MSc, Ann S. LaCasce, MD, Michael Millenson, MD, Nademanee Auayporn, MD, Joyce Niland, PhD, Anna Ter Veer, MS, Andrew D. Zelenetz, MD, Jane C. Weeks, MD

Blood (2005) 106 (11): 1335.

https://doi.org/10.1182/blood.V106.11.1335.1335

Published: 2005

Journal Articles

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project.

Jonathan W. Friedberg, MD, MMSc, Michelle E. Kho, PT, MSc, Eva M. Lepisto, MSc, MA, M. Alma Rodriguez, MD, Anna TerVeer, MSc, Ann S. LaCasce, MD, Auyporn P. Nademanee, MD, Michael Millenson, MD, Myron Czuczman, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD, PhD, Jane C. Weeks, MD, MSc

Blood (2004) 104 (11): 1391.

https://doi.org/10.1182/blood.V104.11.1391.1391

Published: 2004

NARROW

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Mutations in the Phosphoinositide 3-Kinase Pathway (PI3K) Are Associated with Poor Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Mutation Spectrum of Transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma and Comparison with De Novo Diffuse Large B-Cell Lymphoma

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only